Physician profile
Christopher D Kullas
NPI 1871563429
$985.49
in general payments reported to CMS, 2019-2025
19 companies · $166 in 2025
The $166 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $72.75 · 2021: $37.48 · 2022: $197 · 2023: $174 · 2024: $218 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $557.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $195.72 | 2019-2025 | Argos, Clareon |
| Apellis Pharmaceuticals, INC. | $103.75 | 2024 | Syfovre |
| Rayner Intraocular Lenses Limited | $100.59 | 2022-2025 | Rayone Emv, Rayone Aspheric, Rayone Spheric |
| Abbvie INC. | $76.69 | 2022-2024 | |
| Horizon Therapeutics Plc | $73.94 | 2019-2022 | |
| Oyster Point Pharma, INC. | $67.53 | 2022-2024 | Tyrvaya, Ryzumvi |
| Allergan, INC. | $65.86 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $39.53 | 2024-2025 | Miebo, Xiidra |
| Glaukos Corporation | $37.30 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $33.11 | 2022-2023 | |
| Dompe US, INC. | $32.33 | 2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $29.09 | 2019 | |
| Ani Pharmaceuticals, INC. | $26.02 | 2024 | Purified Cortrophin Gel |
| Merz Pharmaceuticals, LLC | $22.14 | 2025 | Xeomin |
| Glaxosmithkline, LLC. | $21.91 | 2025 | Blenrep |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $19.76 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $15.82 | 2025 | Cirrus Hd-Oct |
| Omeros Corporation | $12.73 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Kullas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.